Navigation Links
Genous in Medical Technology

Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents

Risk of Late Thrombosis is Minimized with Genous Stent BARCELONA, Spain, May 23, 2007 /PRNewswire/ -- The efficacy of OrbusNeich's Genous(TM) Bio-engineered R stent compares favorably to that of drug-eluting stents, while the risk of late thrombosis is minimized with the Genous stent, according to...

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

...ble results in patients treated with the company's genous Bio-engineered R stent, the world's first pro-heal...scularization (TLR) rates (15.3% vs 13.7%) for the genous Bio-engineered R stent compared to Boston Scientif...hromboses. There were no thrombotic events in the genous treated group at any time period (0.0%). Myocardi...

Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)

...nd efficacy in the real-world use of the company's genous Bio-engineered R stent. Presented by Professor R...te of 8.5%. "The data further support the use of genous as an alternative to drug- eluting stents, especia...stry with 5,000 enrolled patients treated with the genous Bio-engineered R stent. The study protocol recomme...

Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008

... the world's first pro-healing stent, OrbusNeich's genous Bio-engineered R stent, will be presented next wee...cademic Medical Center in Amsterdam will provide a genous clinical program update in an oral presentation at...a Real World Experience in Patients Treated with a genous EPC Capturing Stent," the poster will reflect the ...

Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents

... of Interventional Cardiology demonstrate that the genous Bio-engineered R stent has better outcomes when co...percutaneous coronary intervention with either the genous stent or a TAXUS(R) and CYPHER(R) stent at the uni...rsus 5.8% for DES. "Our results suggest that the genous Bio-engineered R stent is safe and effective in hi...

Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents

...m at EuroPCR 2008 support the use of the company's genous Bio-engineered R stent, the world's first pro-heal...(TVF) rates at 12-month follow-up for OrbusNeich's genous Bio-engineered R stent and Boston Scientific's Tax...events, while there were no reported events in the genous group. TRIAS HR Pilot is a randomized, 193-patient...

Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008

...nth follow up data on 78 patients treated with the genous stent. Jonathan Hill, M.D., of King's College, L...Hospital, Singapore will present on the use of the genous Bio-engineered R stent in acute myocardial infarct... single blind study called TRIAS HR Pilot with the genous stent randomized with a drug eluting stent. In add...

Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology

... of the first-ever pro-healing stent, OrbusNeich's genous Bio-engineered R stent, is the subject of a sympos....-1:35 p.m. -- The latest clinical update on the genous technology by Federico Piscione, M.D., of Fede... on the data we've seen with the real-world use of genous and in recent clinical trials, we believe that the...

OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial

...s who received OrbusNeich's pro-healing stent, the genous Bio-engineered R stent, had significantly fewer ma...ES. "Our findings suggest that the deployment of genous stents in a consecutive series of high-risk patien...otoxic agents to inhibit neointimal proliferation, genous attracts circulating endothelial progenitor cells ...

Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis

...follow-up, the majority of patients who received a genous stent were on single antiplatelet therapy, whi... therapy -- One acute stent thrombosis in the genous arm, while there was one acute, one subacute ... for the large-scale TRIAS study that will compare genous to both drug-eluting and bare metal stents." For ...
Genous in Biological Technology

OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients

...arget lesion revascularization (TLR) rate with the genous treated patient group compared with patients recei...mbosis events at any time period in the 98 patient genous group with only one month of dual antiplatelet the...e composite of death and myocardial infarction for genous was 4.1% versus 7.3% for Taxus. "Within a month w...

Interim Analysis of Data from e-HEALING Registry of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008

...om e-HEALING, a global post-marketing surveillance registry of OrbusNeich's genous Bio-engineered R stent, will be presented next week at the American Heart A...reatment of vascular diseases. The company's product portfolio includes the genous Bio-engineered R stent, an antibody-coated device that is the first-ever st...

OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports

...rnal (2008; Vol. 155, Issue 1: 128-132). The paper, based on a study of 120 acute ST-elevation myocardial infarction (STEMI) patients who received a genous stent, reports there was no incidence of late thrombosis and that the revascularization rate of 2.5% at six months is highly acceptable when compared ...
Other Tags
(Date:7/13/2014)... Advanced boilers are preferred over ... of fossil fuels, produce high-capacity power, emit fewer ... global warming and climate change concerns, many countries ... gas emissions and pollutants coming from fossilfuel-based power ... global advance boilers market., The global power rental ...
(Date:7/13/2014)... 13, 2014 According to a ... Computing Market by Component (processor, GPU, DSP, connectivity), ... Medical), and Geography - Forecast and Analysis to ... Processing & Computing Market is expected to reach ... of 20.75% from 2014 to 2020. , Browse ...
(Date:7/13/2014)... A Massachusetts couple who have done ... associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) finally ... regulators, as they presented poignant testimony on the second ... (FDA) advisory panel meeting convened to address the issue, ... Democrat and Chronicle, Dr. Hooman Noorchashm and his wife, ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
(Date:7/11/2014)... Researchers from Salk Institute for Biological Studies, BGI, ... the safety and reliability of the existing targeted ... method, TALEN-HDAdV, which could significantly increased gene-correction efficiency ... study published online in Cell Stell Cell ... cell-based gene therapy. , The combination of stem ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
Other Contents